Physician profile
Adam C Deising
NPI 1235285222
$131,318.85
in general payments reported to CMS, 2019-2025
39 companies · $62K in 2025
The $62K reported for 2025 was more than what 88% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,311 · 2020: $15.42 · 2021: $638 · 2022: $9,221 · 2023: $23K · 2024: $32K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Travel and Lodging: $8,953 · Food and Beverage: $7,491 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,763.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,850.00 |
| Travel and Lodging | $8,952.80 |
| Food and Beverage | $7,490.94 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $41,305.92 | 2022-2024 | Terlivaz |
| Novo Nordisk INC | $40,153.94 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39,449.09 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $5,135.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,176.22 | 2021-2025 | Entyvio, Livtencity, Gattex |
| Abbvie INC. | $742.83 | 2021-2025 | Linzess, Viberzi, Creon |
| Intercept Pharmaceuticals, INC. | $486.62 | 2022-2025 | Ocaliva |
| Janssen Biotech, INC. | $481.87 | 2021-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $274.56 | 2022-2025 | Dupixent |
| Genzyme Corporation | $253.18 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $250.74 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $231.95 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $203.61 | 2021-2025 | Prevymis, Dificid, Zerbaxa |
| Lilly USA, LLC | $113.35 | 2024-2025 | Omvoh |
| Astrazeneca Pharmaceuticals Lp | $104.61 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $103.72 | 2025 | Voquezna |
| Ethicon US, LLC | $77.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $74.39 | 2023-2025 | Rebyota |
| Qol Medical, LLC | $64.45 | 2021-2025 | Sucraid |
| Celltrion USA INC. | $60.41 | 2025 | Vegzelma |
| Eisai INC. | $55.20 | 2024-2025 | |
| Braintree Laboratories, INC. | $51.34 | 2022-2024 | Sutab, Suflave |
| Pfizer INC. | $50.64 | 2022-2023 | |
| Evoke Pharma, INC. | $46.23 | 2024-2025 | |
| Daiichi Sankyo INC. | $40.61 | 2022-2024 | Injectafer |
| Redhill Biopharma INC. | $39.64 | 2024 | Talicia |
| Orphalan INC | $37.62 | 2025 | Cuvrior |
| Blueprint Medicines Corporation | $31.30 | 2023 | |
| Genentech USA, INC. | $29.84 | 2025 | Tecentriq |
| Azurity Pharmaceuticals, INC. | $29.58 | 2025 | Triptodur |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.95 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $23.74 | 2024 | Envarsus |
| Vivus LLC | $23.44 | 2025 | Qsymia |
| Alnylam Pharmaceuticals INC. | $21.68 | 2021 | |
| Steris Corporation | $18.99 | 2025 | |
| Abbott Laboratories | $16.74 | 2025 | Amplatzer Talisman |
| Cook Medical LLC | $15.42 | 2020 | |
| Eurofins Viracor, LLC | $13.93 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Deising listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.